Author

Kimmo Porkka

Professor of hematology, Helsinki University Hospital Cancer Center - Cited by 19,990 - acute leukemias - data science

Biography

Dr. Kimmo Porkka is an eminent author in the field of leukemia and Medicine. He is currently associated with the Hematology Research Unit, Biomedicum Helsinki, Helsinki University Central Hospital, Helsinki, Finland.
Title
Cited by
Year
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ...Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022202
482
2022
Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS …
AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, ...Blood 138, 244, 2021202
54
2021
Implementing a functional precision medicine tumor board for acute myeloid leukemia
D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ...Cancer Discovery 12 (2), 388-401, 2022202
49
2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
GJ Roboz, F Ravandi, AH Wei, H Dombret, F Thol, MT Voso, AC Schuh, ...Blood, The Journal of the American Society of Hematology 139 (14), 2145-2155, 2022202
34
2022
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
WY Lin, SE Fordham, E Hungate, NJ Sunter, C Elstob, Y Xu, C Park, ...Nature Communications 12 (1), 6233, 2021202
14
2021
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
H Döhner, AH Wei, GJ Roboz, P Montesinos, FR Thol, F Ravandi, ...Blood, The Journal of the American Society of Hematology 140 (15), 1674-165, 2022202
8
2022
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ...Blood, The Journal of the American Society of Hematology 141 (13), 1610-1625, 2023202
8
2023
Long-term overall survival (OS) with oral azacitidine (Oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC): updated …
AH Wei, H Döhner, H Sayar, F Ravandi, P Montesinos, H Dombret, ...Blood 138, 871, 2021202
6
2021
Prognostic impact of NPM1 and FLT3 mutations at diagnosis and presence of measurable residual disease (MRD) after intensive chemotherapy (IC) for patients with acute myeloid …
H Döhner, AH Wei, GJ Roboz, P Montesinos, FR Thol, F Ravandi, ...Blood 138, 804, 2021202
6
2021
Targeting apoptosis pathways with BCL2 and MDM2 inhibitors in adult B-cell acute lymphoblastic leukemia
H Hohtari, M Kankainen, S Adnan-Awad, B Yadav, S Potdar, A Ianevski, ...HemaSphere (3), 2022202
6
2022
Allogeneic hematopoietic cell transplantation outcomes of patients with R/R AML or higher-risk MDS treated with the TIM-3 inhibitor MBG453 (sabatolimab) and hypomethylating agents
Allogeneic hematopoietic cell transplantation outcomes of patients with R/R AML or higher-risk MDS treated with the TIM-3 inhibitor MBG43 (sabatolimab) and hypomethylating agentsAM Brunner, E Traer, N Vey, S Scholl, N Tovar, K Porkka, R Narayan, ...Blood 138, 3677, 2021202
5
2021
Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
H Hohtari, N Pallisgaard, M Kankainen, P Ellonen, O Brück, T Siitonen, ...Haematologica 107 (8), 1971, 2022202
3
2022
Preliminary results from a phase Ib study exploring MDM2 inhibitor siremadlin (HDM201) in combination with B-cell lymphoma-2 (BCL-2) Inhibitor venetoclax in patients with acute …
AH Wei, M Breccia, M Ooi, MTC Romero, F Ciceri, HP Erba, A Gaur, ...Blood 18, 128, 2021202
3
2021
MDS-420: sabatolimab plus hypomethylating agents (HMAs) in patients with high-/very high-risk myelodysplastic syndrome (HR/vHR-MDS) and newly diagnosed acute myeloid leukemia …
G Garcia-Manero, AH Wei, K Porkka, S Knapper, E Traer, S Scholl, N Vey, ...Clinical Lymphoma Myeloma and Leukemia 21, S50, 2021202
3
2021
Incidence of myelodysplastic syndromes in Finland 1997–2016
S Kontro, J Raitanen, K Porkka, A AuvinenLeukemia Research 116, 10689, 2022202
3
2022
An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
W Kong, L He, J Zhu, O Brück, K Porkka, CA Heckman, S Zhu, T AittokallioLeukemia 6 (10), 284-295, 2022202
3
2022
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
J Huuhtanen, M Ilander, B Yadav, OMJ Dufva, H Lähteenmäki, T Kasanen, ...The Journal of clinical investigation 13 (17), 0
2
2022
Early response evaluation by single cell signaling profiling in acute myeloid leukemia
BS Tislevoll, M Hellesøy, OHE Fagerholt, SE Gullaksen, A Srivastava, ...Nature communications 14 (1), 115, 030
2
2023
P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 …
P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-00 …AH Wei, H Döhner, H Sayar, F Ravandi, P Montesinos, H Dombret, ...HemaSphere 6, 397-398, 2022202
1
2022
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
WY Lin, SE Fordham, E Hungate, NJ Sunter, C Elstob, Y Xu, C Park, ...Nature Communications 3 (), 2, 2022202
1
2022

Referred From: https://scholar.google.co.uk/citations?user=_E0IBNMAAAAJ&hl=en

Cited by
Citations 19990
h-index 67
i10-index 179
Recommended Journals
Open Access Journals